Full Text (PDF)
Case Report

A Rare Serious Ocular Side Effect of Topiramate: Bilateral Acute Angle Closure Glaucoma

Mukundkumar V. Patel, Consultant Physician, Dhruv Healthcare MultiSpeciality Hospital, 59, Rajeshwari Society, CTM Crossroad, Amraiwadi, Ahmedabad, Gujarat 380026, India. , Dhruvkumar M. Patel1 , Mukundkumar V. Patel2 , Ajay V. Garg3

Author Information

Licence:




Indian Journal of Emergency Medicine 3(2):p 255-257, Jul-Dec 2017. | DOI: http://dx.doi.org/10.21088/ijem.2395.311X.3217.14

How Cite This Article:


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Topiramate is an anticonvulsant drug which is also used for migraine prophylaxis. It has many neurological and psychiatric side effects in addition to diarrhoea and weight loss. It can cause serious ocular side effects like sudden dimness of vision secondary to acute narrow angle glaucoma and or myopia. These sideeffects usually occur at more than 200 mg per day dose and after 4 to 6 weeks of starting treatment with the drug. We report a case of 20years old female who developed sudden dimness of vision in both eyes after migraine prophylaxis with topiramate 25 mg daily for seven days. Her cause of this vision problem was secondary acute angle glaucoma and myopia because of topiramate. After stopping the drug her vision became normal within seven days. Clinicians should explain ocular side effects of topiramate and if he/she develops such visual problems, he/she should stop the drug and consult clinician immediately.

Keywords: Rare Ocular Side Effect; Topiramate. 


References

No records found.


About this article


Cite this article


Licence:




Received Accepted Published
N/A N/A N/A

DOI: http://dx.doi.org/10.21088/ijem.2395.311X.3217.14

Keywords


Article Level Metrics

Last Updated

Monday 22 June 2026, 06:05:14 (IST)


2182

Accesses

3
767
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share